Almroth G, Eneström S, Hed J, Samuelsson I, Sjöström P
Department of Nephrology, University Hospital of Linköping, Sweden.
J Intern Med. 1992 Jan;231(1):37-42. doi: 10.1111/j.1365-2796.1992.tb00496.x.
Clinical and laboratory findings and drug history were studied in 17 patients with suspected hydralazine-associated nephritis, five of whom only had renal disease, while twelve also had extrarenal manifestations. Renal biopsies revealed extracapillary proliferative or focal segmental proliferative glomerulonephritis in 10 patients, and tubulo-interstitial nephritis in five patients. Antinuclear antibody (ANA) was found in 16 patients, but none of the 14 patients tested had antibodies to DNA. Tests for antibodies to myeloperoxidase (anti-MPO) and antibodies to neutrophil cytoplasm antigen (ANCA) were performed by ELISA. Twelve of the 14 patients tested had anti-MPO; five of these 14 patients had ANCA, while one had borderline levels. These findings suggest that hydralazine facilitates the induction of a systemic disease with multiple autoantibody production.
对17例疑似肼屈嗪相关性肾炎患者的临床、实验室检查结果及用药史进行了研究。其中5例仅有肾脏疾病，12例还有肾外表现。肾活检显示，10例患者为毛细血管外增生性或局灶节段性增生性肾小球肾炎，5例患者为肾小管间质性肾炎。16例患者检测出抗核抗体（ANA），但14例接受检测的患者均未检测出抗DNA抗体。采用酶联免疫吸附测定法（ELISA）检测髓过氧化物酶抗体（抗MPO）和中性粒细胞胞浆抗原抗体（ANCA）。14例接受检测的患者中有12例检测出抗MPO；这14例患者中有5例检测出ANCA，1例为临界水平。这些发现表明，肼屈嗪促进了一种伴有多种自身抗体产生的全身性疾病的诱发。
